ArticleCancer research2022
EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
4.5field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 68 citations in OpenAlex.
- Advancing antibody drug conjugates in gastrointestinal cancers.British journal of cancer · 2026Review
- PARP inhibition enhances the antitumor activity of HER3-DXd in non-small cell lung cancer.Cell reports. Medicine · 2026Article
- Black Sheep: Pseudokinases Bucking the Trend to Reveal Non-Catalytic Kinase Functions.IUBMB life · 2026Review
- Targeting EGFR Endocytosis and Signaling for Cancer Drug Delivery and Cancer Treatment.Cancers · 2026Review
- Review
- Antibody-drug conjugates in breast cancer: from mechanism to revolutionizing clinical practice.Molecular cancer · 2026Review
- Roles of Her3 in carcinogenesis and advances in Her3-targeted cancer therapy.Discover oncology · 2026Review
- The Impact of HER3 Dynamics Altered by HER3-DXd Alone and in Combination with Driver Oncogene Inhibitors on HER3-DXd Efficacy.International journal of molecular sciences · 2026Article
- A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- HER3-targeting Antibody-drug Conjugates Therapy for Solid Tumors: Recent Advances and Future Potentials.Current medicinal chemistry · 2026Review
- Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC - mechanisms and evolving treatment approaches.Nature reviews. Clinical oncology · 2026Review
- Antibody-drug conjugates in colorectal cancer: advances in targeted delivery and personalized oncology.Frontiers in bioengineering and biotechnology · 2026Review
- Leveraging Acquired EGFR-TKI-Resistant Models to Identify MUC16 as a Therapeutic Vulnerability in Lung Adenocarcinoma.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models.Cell reports. Medicine · 2025Article
- Antibody-drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives.NPJ breast cancer · 2025Review
- [Advances in Antibody-drug Conjugates for Non-small Cell Lung Cancer after Resistance to First-line Therapy].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- Patient-derived xenograft models: Current status, challenges, and innovations in cancer research.Genes & diseases · 2025Review
- Exposure-Response Relationships in Patients with Non-Small-Cell Lung Cancer and Other Solid Tumors Treated with Patritumab Deruxtecan (HER3-DXd).Clinical pharmacology and therapeutics · 2025Article
- Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models.bioRxiv : the preprint server for biology · 2025Article
- Targeting Lung Cancer with Precision: The ADC Therapeutic Revolution.Current oncology reports · 2025Review
Corrections and comments
- Commented on by
Authors and funding
24 authors at 4 institutions in 4 countries.
Heidi M HaikalaLowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-8465-8568
Timothy LopezLowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-6050-5153
Jens KöhlerLowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-9922-6469
Pinar O EserLowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0003-1555-4981
Man XuRobert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Qing ZengRobert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Tyler J TecenoRobert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Kenneth NgoRobert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Yutong ZhaoLowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Elena V IvanovaRobert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Arrien A BertramLowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0001-7237-0623
Brittaney A LeeperExperimental Therapeutics Core, Dana-Farber Cancer Institute, Boston, Massachusetts.
Emily S ChambersLowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0003-4076-506X
Anika E AdeniLowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Luke J TausRobert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0003-0512-2536
Mari KuraguchiRobert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Paul T KirschmeierRobert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Channing YuGlobal Oncology R&D, Daiichi Sankyo, Basking Ridge, New Jersey.ORCID 0000-0002-3231-2565
Yoshinobu ShioseDS Oncology Function Biomarker and Translational Research Department, Daiichi Sankyo, Shinagawa R&D Center, Tokyo, Japan.
Yasuki KamaiOncology Research Laboratories I, Daiichi Sankyo Co., Ltd.
Yang QiuGlobal Oncology R&D, Daiichi Sankyo, Basking Ridge, New Jersey.
Cloud P PaweletzRobert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Prafulla C GokhaleRobert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Pasi A JänneLowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. pasi_janne@dfci.harvard.edu.ORCID 0000-0002-7821-4928
Dana-Farber Cancer Institute · USHarvard University · USDaiichi Sankyo (Germany) · DEDaiichi Sankyo (United States) · US
Funding
Development of Combination Therapies to Delay/Prevent Acquired Drug ResistanceR35CA220497 · NCI · DANA-FARBER CANCER INST · PI JANNE, PASI A · 2018 to 2024
$7.2MNCI NIH HHS R35 CA220497
Abstract
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are the standard-of-care treatment for
Indexed as
AnimalsAntineoplastic AgentsApoptosisCell Culture TechniquesCell Line, TumorErbB ReceptorsHumansImmunoconjugatesMiceReceptor, ErbB-3Antineoplastic AgentsErbB ReceptorsImmunoconjugatesReceptor, ErbB-3
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.